Valuation: Delcath Systems, Inc.

Capitalization 382M 329M 301M 287M 526M 36.66B 535M 3.61B 1.4B 17.41B 1.43B 1.4B 60.64B P/E ratio 2026 *
-18.5x
P/E ratio 2027 * -22.7x
Enterprise value 382M 329M 301M 287M 526M 36.66B 535M 3.61B 1.4B 17.41B 1.43B 1.4B 60.64B EV / Sales 2026 *
3.68x
EV / Sales 2027 * 2.85x
Free-Float
91.87%
Yield 2026 *
-
Yield 2027 * -
1 day-3.40%
1 week-3.57%
Current month+6.65%
1 month+0.73%
3 months+18.90%
6 months+23.96%
Current year+9.60%
1 week 10.79
Extreme 10.79
11.72
1 month 10.05
Extreme 10.05
12.27
Current year 8.48
Extreme 8.485
12.27
1 year 8.12
Extreme 8.12
18.23
3 years 2.25
Extreme 2.25
18.23
5 years 2.25
Extreme 2.25
18.23
10 years 2.25
Extreme 2.25
1,000,000
Manager TitleAgeSince
Chief Executive Officer 62 2020-09-30
Director of Finance/CFO 47 2023-04-30
Chief Operating Officer 55 2024-03-17
Director TitleAgeSince
Chairman 62 2023-02-15
Director/Board Member 70 2020-02-13
Director/Board Member 60 2020-05-05
Change 5d. change 1-year change 3-years change Capi.($)
-3.40%-3.57%-31.03%+82.67% 382M
+0.10%-1.32%-25.41%-41.38% 16.95B
+2.64%+0.34%-34.85%-35.71% 13.57B
-0.32%+3.33% - - 4.61B
+0.95%-3.56%-63.90%-61.26% 4.5B
+0.24%-1.53%+55.29%-6.01% 1.83B
-0.94%-3.49%-16.40%-16.53% 1.74B
-0.93%-3.56%-36.73%-60.75% 1.39B
-16.32%+83.75% - - 945M
0.00%-5.39%+45.11%+147.44% 691M
Average -1.80%+6.43%-13.49%+1.06% 4.66B
Weighted average by Cap. +0.45%+0.88%-28.03%-35.38%

Financials

2026 *2027 *
Net sales 104M 89.38M 81.72M 77.97M 143M 9.97B 145M 980M 379M 4.73B 390M 381M 16.48B 134M 115M 105M 101M 184M 12.86B 187M 1.27B 490M 6.1B 503M 492M 21.27B
Net income -21.94M -18.88M -17.26M -16.47M -30.19M -2.1B -30.69M -207M -80.13M -999M -82.33M -80.57M -3.48B -18.01M -15.49M -14.17M -13.52M -24.78M -1.73B -25.19M -170M -65.77M -820M -67.57M -66.13M -2.86B
Net Debt - -
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
156
Date Price Change Volume
26-05-15 11.07 $ -3.40% 550,641
26-05-14 11.46 $ -1.29% 423,596
26-05-13 11.61 $ +2.38% 685,897
26-05-12 11.34 $ +2.53% 639,024
26-05-11 11.06 $ -3.66% 667,770
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
11.07USD
Average target price
20.79USD
Spread / Average Target
+87.83%

Quarterly revenue - Rate of surprise